Sarepta: Is There Upside After Shares Soar on New Drug Application Decision?

What makes a stock jump nearly 50%? In the case of Sarepta Therapeutics (SRPT), it’s the FDA giving the go-ahead to begin filing a rolling new-drug application. Canaccord Genuity’s Adam Walsh explains: We are upgrading shares of Sarepta to BUY from Hold on reduced near-term regulatory risk and potential upcoming catalysts following the company’s positive [...]